非小细胞肺癌合并脑转移患者预后模型的构建研究

doi:10.3969/j.issn.1006-5253.2023.03.005

摘要
图/表
参考文献
相关文章 (11)

全文: PDF (3814 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

文章导读

摘要目的研究旨在评估新诊断非小细胞肺癌(NSCLC)合并脑转移患者的预后因素，并构建列线图来预测总生存期(OS)。方法从SEER数据库中纳入2010—2016年新诊断为NSCLC伴脑转移患者，随机以7∶3分为建模组和验证组；采用Cox比例风险回归分析NSCLC合并脑转移患者的独立预后因素；使用R软件构建列线图并对其进行区分度、一致性、有效性评价，最终绘制1～3年生存曲线。结果 6 102例合并脑转移的NSCLC患者被纳入分析，年龄、种族、性别、组织学类型、肝转移、肺转移、骨转移、Grade分级、T分期、N分期、手术、化疗及放疗是NSCLC合并脑转移患者的独立预后因素。综合分析建立列线图，通过区分度、一致性、有效性评价验证，该临床预测模型在预测预后方面具有较好的效果。结论通过构建临床预测模型，可以有效预测NSCLC合并脑转移患者个体的总生存期，对临床医生和患者具有指导意义。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	卞厚磊
	高学军

关键词 ：非小细胞肺癌, 脑转移, 列线图, SEER

Abstract：Objective Patients with non-small cell lung cancer (NSCLC) complicated with brain metastases (BM) have poor prognosis. This study aimed to evaluate the prognostic factors of BM in newly diagnosed NSCLC patients and construct a nomogram to predict the overall survival (OS).Methods We included NSCLC patients with BM diagnosed from 2010 to 2016 in SEER and they were randomly divided into the modeling group and the validation group at 7∶3. The independent prognostic factors for NSCLC with BM were determined by Cox proportional hazard regression analysis. R software was used to construct a nomogram and evaluate its differentiation, consistency and effectiveness, and finally draw a 1-3 year survival curve.Results We finally included 6 102 NSCLC patients with BM for analysis. Age, race, gender, histologic type, liver metastasis, lung metastasis, bone metastasis, Grade grading, T staging, N staging, surgery, chemotherapy and radiotherapy were identified as the prognostic factors for NSCLC with BM and integrated to establish the nomogram. The calibration, receiver operating characteristic curve, and decision curve analyses also showed that the clinical prediction model performed satisfactorily in predicting prognosis.Conclusion The construction of a clinical prediction model could effectively predict the overall survival of patients with NSCLC with BM, which has guiding significance for clinicians and patients.

Key words： non-small cell lung cancer (NSCLC) brain metastases (BM) nomogram SEER

收稿日期: 2023-02-01

PACS:

基金资助:

通讯作者: 高学军，Email：17355022226@qq.com

引用本文:

卞厚磊，高学军. 非小细胞肺癌合并脑转移患者预后模型的构建研究[J]. 中国医院统计, 2023, 30(3): 183-190.
Bian Houlei，Gao Xuejun. Construction of prognostic model of nonsmall cell lung cancer patients with brain metastases

. journal1, 2023, 30(3): 183-190.

链接本文:

http://manu58.magtech.com.cn/Jwk_zgyytj/CN/10.3969/j.issn.1006-5253.2023.03.005 或 http://manu58.magtech.com.cn/Jwk_zgyytj/CN/Y2023/V30/I3/183

［1］ETTINGER D S, WOOD D E, AISNER D L, et al. Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology［J］. J Natl Compr Canc Netw, 2022, 20(5):497-530. DOI: 10.6004/jnccn.2022.0025.

［2］SIEGEL R L, MILLER K D, FUCHS H E , et al. Cancer statistics, 2021［J］. CA A Cancer J Clin, 2021, 71(1):7-33. DOI: 10.3322/caac.21654.

［3］SATHIAKUMAR N, DELZELL E, MORRISEY M A, et al. Mortality following bone metastasis and skeletal-related events among patients 65 years and above with lung cancer: A population-based analysis of U.S. Medicare beneficiaries, 1999-2006［J］. Lung India, 2013, 30(1):20-26. DOI: 10.4103/0970-2113.106127.

［4］DECROISETTE C, MONNET I, BERARD H, et al. Epidemiology and treatment costs of bone metastases from lung cancer: A French prospective, observational, multicenter study (GFPC 0601)［J］. J Thorac Oncol,2011,6(3):576-582.DOI:10.1097/JTO.0b013e318206a1e3.

［5］VILLANO J L, DURBIN E B, NORMANDEAU C, et al. Incidence of brain metastasis at initial presentation of lung cancer［J］. Neuro Oncol, 2015, 17(1):122-128. DOI: 10.1093/neuonc/nou099.

［6］ALI A, GOFFIN J R, ARNOLD A, et al. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases［J］. Curr Oncol, 2013, 20(4):e300-e306. DOI: 10.3747/co.20.1481.

［7］PARK H S, DECKER R H, WILSON L D, et al. Prophylactic cranial irradiation for patients with locally advanced non-small-cell lung cancer at high risk for brain metastases［J］. Clin Lung Cancer, 2015, 16(4):292-297. DOI: 10.1016/j.cllc.2014.11.005.

［8］DE COS J S, GONZ A LEZ M A S, MONTERO M V, et al. Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors［J］. Lung Cancer, 2009, 63(1):140-145. DOI: 10.1016/j.lungcan.2008.04.013.

［9］DAVID E A, CANTER R J, CHEN Y J, et al. Surgical management of advanced non-small cell lung cancer is decreasing but is associated with improved survival［J］. Ann Thorac Surg, 2016, 102(4):1101-1109. DOI: 10.1016/j.athoracsur.2016.04.058.

［10］纪环，周菊英，马辰莺，等．非小细胞肺癌脑转移的放疗进展［J］．国际肿瘤学杂志，2022，49(3)：181-184．DOI: 10.3760/cma.j.cn371439-20220104-00031.

［11］DAVID E A, CANTER R J, CHEN Y J, et al. Surgical management of advanced non-small cell lung cancer is decreasing but is associated with improved survival［J］. Ann Thorac Surg, 2016, 102(4):1101-1109. DOI: 10.1016/j.athoracsur.2016.04.058.

［12］ABDEL-RAHMAN O. Outcomes of surgery as part of the management of metastatic non-small-cell lung cancer: A surveillance, epidemiology and end results database analysis［J］. Cancer Invest, 2018, 36(4):238-245. DOI: 10.1080/07357907.2018.1466895.

［13］王丽娟，蒋国樑，付晓龙，等．肺癌脑转移放射和化疗的综合治疗［J］．中华放射肿瘤学杂志，1993，2(4)：263．DOI: 10.3760/cma.j.issn.1004-4221.1993.04.133.

［14］王淼，张俊，覃桂珍，等．初诊脑转移肺腺癌患者全身治疗联合脑部放疗的疗效和安全性［J］．中华肿瘤防治杂志，2021，28(9)：682-687．DOI: 10.16073/j.cnki.cjcpt.2021.09.08.

［15］TSAO M, XU W, SAHGAL A. A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases［J］. Cancer, 2012, 118(9):2486-2493. DOI: 10.1002/cncr.26515.

［16］杜倩宇，李曼，王效静，等．肺癌化疗抵抗相关因素研究进展［J］．中国肿瘤，2021，30(11)：875-882．DOI: 10.11735/j.issn.1004-0242.2021.11.A012.

［17］RICHARDS T B, HENLEY S J, PUCKETT M C, et al. Lung cancer survival in the United States by race and stage (2001-2009):Findings from the CONCORD-2 study［J］. Cancer, 2017, 123(Suppl 24):5079-5099. DOI: 10.1002/cncr.31029.

［18］SPERDUTO P W, CHAO S T, SNEED P K, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: A multi-institutional analysis of -4, 259-patients［J］. Int J Radiat Oncol Biol Phys, 2010, 77(3):655-661. DOI: 10.1016/j.ijrobp.2009.08.025.

［19］SCULIER J P, CHANSKY K, CROWLEY J J, et al. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition［J］. J Thorac Oncol, 2008, 3(5):457-466. DOI: 10.1097/JTO.0b013e31816de2b8.

［20］路友华，王炳翔，王家林，等．中国居民1990—2019年肺癌及其危险因素疾病负担变化趋势分析［J］．中国公共卫生，2022，38(5)：513-517．DOI: 10.11847/zgggws1137000.